192
Inmunoterapia 3.0: Innovando soluciones para el paciente de hoy
tract. VI. Specific immunotherapy pre-
vents the onset of new sensitizations
in children. J Allergy Clin Immunol
1997;99:450-453.
7.
DURHAM SR, WALKER SM, VARGA EM,
JACOBSON MR, O’BRIEN F, NOBLEW,TILL
SJ, HAMIDQA, NOURI-ARIA KT. Long-term
clinical efficacy of grass-pollen immuno-
therapy. N Engl J Med. 1999;341:468-75
8.
VAN METRE T.E. ET AL. A comparison of
immunotherapy schedules for injection
treatment of ragweed pollen hay fever.
J.Allergy Clin. Immunol. 1982;69:181-93.
9.
Pollinosis 2003. Aerobiological Committee
of the SEAIC.
3.
Norman PS, Lichtenstein LM, Marsh DG.
Studies on allergoids from naturally occu-
ring allergens. IV. Effi cacy and safety of long-
term allergoid treatment of ragweed hay fe-
ver. J Allergy Clin Immunol. 1981;68:460-70.
4.
A. Reuter, D. Lüttkopf and S. Vieths. New
frontiers in allergen standarization. Clin
Exp Allergy 2009; Vol. 39 (3): 307-309.
5.
Guideline on Allergen Products; Produc-
tion and Quality Issues. EMEA/CHMP/
BWP/304821/2007.
6.
DES ROCHES A, PARADIS L, MENARDO
JL, BOUGES S, DAURES JP, BOUSQUET
J. Immunotherapy with a standardized
Dermatophagoides pteronyssinus ex-
